Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MNCs Applaud Shanghai Zhangjiang Hi-tech Park Pilot Program To Accelerate Biomaterial Imports

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Ten research centers in Shanghai Zhangjiang Hi-tech Park have passed inspections by the General Administration of Quality Supervision, Inspection and Quarantine for the first round of a pilot program aimed at simplifying import procedures and at shortening the time it takes to approve imported biomaterial

You may also be interested in...



BIO Welcomes First Chinese Members: Shanghai Zhangjiang Park And Taizhou Medical City

SHANGHAI - BIO, the largest biotechnology organization with 1,200 members around the world, announced its first two members from China - Zhangjiang Hi-tech Park in Shanghai and China Medical City in Taizhou - during the group's annual convention in Chicago

BIO Welcomes First Chinese Members: Shanghai Zhangjiang Park And Taizhou Medical City

SHANGHAI - BIO, the largest biotechnology organization with 1,200 members around the world, announced its first two members from China - Zhangjiang Hi-tech Park in Shanghai and China Medical City in Taizhou - during the group's annual convention in Chicago

Shanghai Hi-Tech Park Acquires Stake In Medical Devices Company MicroPort As Part Of Overhaul Of Shanghai Pharmaceutical Industry

SHANGHAI - Shanghai Zhangjiang Hi-Tech Park Development announced June 27 the company will pay $85.35 million to acquire a 24.4 percent stake in MicroPort Scientific

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel